Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone

European Journal of Cancer

Volumn 34, Issue 2, 1998, Pages 240-245

  Yoneda, T ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; BONE METASTASIS; BREAST METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ANALYSIS; THEORY; TISSUE DISTRIBUTION;

EID: 0032512898     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10132-0     Document Type: Article

References (37)

1. 1. Walther HE. Krebsmetastase A. Basel, Beno Schwabe & Co., Verlag, 1948.
2. 2. Ewing J. A Treatise on Tumors, 3rd edn. Philadelphia, WB Saunders, 1928.
3. 3. Weiss L, Haydock K, Pickern JW, Lane WW. Organ vascularity and metastic frequency. Am J Pathol 1980, 101, 101-114.
4. 4. Hauschka PV, Manrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types of affinity chromatography on heparin sepharose. J Biol Chem 1986, 261, 12665-12674.
5. 5. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1, 571-573.
6. 6. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR. Scanning electron microscopy in bone pathology: review of methods. Potential and applications. Scanning Electron Microsc 1986, 4, 1537-1554.
7. 7. Hiraga T, Nakajima T, Ozawa H. Bone resorption induced by a metastatic human melanoma cell line. Bone 1995, 16, 349-356.
8. 8. Cook GB, Watson FR. Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients. J Urol 1968, 96, 87-96.
9. 9. Scher HI, Chung LWK. Bone metastases: improving the therapeutic index. Semin Oncol 1994, 21, 630-656.
10. 10. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1996, 28, 485-495.
11. 11. Ide H, Katoh M, Sasaki H, et al. Cloning of human bone morphogentetic protein type 1B receptor (BMPR-1B) and its expression in prostate cancer in comparison with other BMPRs. Oncogene 1997, 14, 1377-1382.
12. 12. Gleave M, Hsieh J-T, Gao C, von Eschenbach AC, Chung LWK. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991, 51, 3753-3761.
13. 13. Rossi MC, Zetter BR. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Nad Acad Sci USA 1991, 89, 6197-6201.
14. 14. Smith RC, Litwin MS, Lu Y, Zetter BR. Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nature Med 1995, 10, 1040-1045.
15. 15. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin β15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nature Med 1996, 2, 1322-1328.
16. 16. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1995, 9, 944-949.
17. 17. Roland SI. Calcium studies in ten cases of osteoblastic prostatic metastasis. J Urol 1958, 79, 339-342.
18. 18. Pollard M, Luckert PH. Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells. J Natl Cancer Inst 1985, 75, 949-954.
19. 19. Yoneda T. Mechanisms of preferential metastasis of breast cancer to bone. Int J Oncol 1996, 9, 103-109.
20. 20. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 1994, 32, 73-84.
21. 21. Yoneda T. Arterial microvascularization and breast cancer colonization in bone. J Histol Histopathol 1997, 12(4), 1145-1149.
22. 22. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJP, Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989, 125, 1142-1150.
23. 23. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995, 55, 3551-3557.
24. 24. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a casual role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996, 98, 1544-1549.
25. 25. Iwamura M, di Saint Agnese Pa, Wu G, et al. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1992, 53, 1724-1726.
26. 26. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Met Rev 1995, 14, 351-352.
27. 27. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997, 99, 2509-2517.
28. 28. Liotta LA. Cancer cell invasion and metastasis. Sci Amer 1992 (Feb), 54-63.
29. 29. Jacobs SC, Pikna D, Lawson RK. Prostatic osteoblastic factor. Invest Urol 1979, 3, 195-198.
30. 30. Simpson E, Harrod J, Eilon G, Jacobs JW, Mundy GR. Identification of a messenger ribonucleic acid fraction in human prostatic cancer cells coding for a novel osteoblast-stimulating factor. Endocrinology 1995, 4, 1615-1620.
31. 31. Perkel VS, Mohan S, Herring SJ, Baylink DJ, Linkhart TA. Human prostatic cancer cells, PC3, elaborate mitogenic activity which selectively stimulates human bone cells. Cancer Res 1990, 50, 6902-6907.
32. 32. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994, 24, 204-211.
33. 33. Bentley H, Hamdy FC, Hart KA, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992, 66, 1159-1163.
34. 34. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGHF-β and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Com 1993, 2, 940-947.
35. 35. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994, 54, 2372-2377.
36. 2+ transients. Endocrinology 1994, 2, 596-602.
37. 37. Sehgal I, Powers S, Huntley B, Powis G, Pittlekow M, Maihle NJ. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Nad Acad Sci 1994, 1, 4673-4677.